September 27th 2023
Based on findings from the phase 1/2 BCHILD trial, the FDA approved bosutinib for pediatric chronic myelogenous leukemia.
September 10th 2023
September 8th 2023
Cross Q&A: Role of Olverembatinib in Heavily Pretreated CML
In this cross Q&A, both the Mayo Clinic and UT Southwestern teams share insight on the role of olverembatinib in relapsed/refractory chronic myeloid leukemia.
Olverembatinib Study in Patients With Heavily Pretreated Chronic Myeloid Leukemia
A comprehensive review of chronic myeloid leukemia olverembatinib data led by expert Kebede Begna, MD, from the Mayo Clinic team.
Cross Q&A: Arterial Occlusive Events With Ponatinib in the PACE Trial
Following a review of the retrospective analysis of PACE, experts reflect on its importance in understanding the risk of arterial occlusive events with ponatinib.
Chronic Myeloid Leukemia: Retrospective Analysis of the PACE Study
A focused discussion led by expert Abhishek Mangaonkar, MBBS, on a retrospective analysis elucidating arterial occlusive events within the PACE study.
Cross Q&A: Ponatinib Dosing in Relapsed/Refractory Chronic-Phase CML
Expert perspectives from the Mayo Clinic and UT Southwestern teams on applications of the OPTIC study and optimal ponatinib dosing in chronic myeloid leukemia.
Chronic-Phase CML: The OPTIC Study
Key opinion leader Kebede Begna, MD, reviews data from the OPTIC study focused on ponatinib dosing in chronic-phase CML.
Team Introductions: CML Experts From UT Southwestern vs. Mayo Clinic
Expert panelists from UT Southwestern and the Mayo Clinic introduce themselves and prepare for a team-vs-team debate surrounding recent clinical trial data in chronic myeloid leukemia.
Efficacy Produced from Olverembatinib in Ponatinib-Resistant, T25I-Mutant CML, and Ph-Positive ALL
December 13th 2022Those with chronic myeloid leukemia, Philadelphia chromosome-positive acute lymphoblastic leukemia, and those with CML whose tumors have a T315I mutation, were found to have improved efficacy when olverembatinib was given.
FDA Grants Breakthrough Therapy Designation to Asciminib for 2 CML Indications
February 10th 2021The FDA has granted breakthrough therapy designation to asciminib for the treatment of adult patients with Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase who have been previously treated with 2 or more tyrosine kinase inhibitors; or who harbor the T315I mutation.